Twist Bioscience Launches cfDNA Library Preparation Kit for Liquid Biopsy Applications
February 06 2024 - 7:00AM
Business Wire
High accuracy and detection to identify tumor
variants from degraded and low input samples as well as samples
with limited DNA abundance
Library preparation kit adds to Twist’s
portfolio of tools to enable liquid biopsy applications
Twist Bioscience Corporation (NASDAQ: TWST), a company enabling
customers to succeed through its offering of high-quality synthetic
DNA using its silicon platform, today launched the cfDNA Library
Preparation Kit to enable liquid biopsy research.
Liquid biopsies have gained prominence in critical applications
such as cancer screening, including multi-cancer early detection
screening and monitoring for minimal residual disease (MRD). Liquid
biopsy tests are designed to accurately identify tumor variants
within circulating tumor DNA (ctDNA), which are often difficult to
detect due to degraded or limited DNA presence. The Twist cfDNA
Library Preparation Kit was purpose-built to maximize the number of
unique cfDNA molecules that are captured in library preparation,
for higher confidence in the accuracy and sensitivity of liquid
biopsy tests.
“Liquid biopsies can be life changing for patients, enabling
earlier detection of cancer and profiling each patient’s unique
tumor to inform personalized treatment plans,” said Emily M.
Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “Even with
advancements in the sensitivity of tests that have enabled the
liquid biopsy field to expand, some tumor variants remain
incredibly difficult for researchers to detect in the earlier
stages of disease. With exceptional accuracy and sensitivity
enabled by high conversion rates, the Twist cfDNA Library
Preparation Kit can help push the limit of detection and detect
lower frequency variants that can be missed by other on market
library preparation solutions.”
The Twist cfDNA Library Preparation Kit adds to Twist’s growing
portfolio of tools to support the research and development of
liquid biopsy assays, which also includes the recently launched
Twist cfDNA Pan-Cancer Reference Standard v2. The reference
standards are a tool for researchers to use in the development and
quality monitoring of clinically relevant variants for developing
NGS-based assays. The updated reference standards include one of
the industry-leading numbers of circulating tumor DNA (ctDNA)
variants and clean background cfDNA for a significantly lower
background error rate. The reference standards can be seamlessly
integrated into Twist’s suite of target enrichment systems and
custom capture panels.
Twist cfDNA Library Preparation Kit
The Twist cfDNA Library Preparation Kit can address challenges
associated with library preparation from circulating cfDNA with
reliable and robust performance from as little as 1ng sample input.
It can detect even rare allele variants due to its high conversion
rate. The cfDNA kit protocols minimize sample handling for a
streamlined workflow and results delivered within two hours. The
Twist cfDNA Library Preparation Kits are available in two
configurations: the cfDNA Library Preparation Kit for whole genome
sequencing (WGS) workflows and the Twist Library Preparation and
Hyb Mix Kit for target enrichment.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic
biology and genomics company that has developed a disruptive DNA
synthesis platform to industrialize the engineering of biology. The
core of the platform is a proprietary technology that pioneers a
new method of manufacturing synthetic DNA by “writing” DNA on a
silicon chip. Twist is leveraging its unique technology to
manufacture a broad range of synthetic DNA-based products,
including synthetic genes, tools for next-generation sequencing
(NGS) preparation, and antibody libraries for drug discovery and
development. Twist is also pursuing longer-term opportunities in
digital data storage in DNA and biologics drug discovery. Twist
makes products for use across many industries including healthcare,
industrial chemicals, agriculture and academic research.
Follow us on Twitter | Facebook | LinkedIn | YouTube |
Instagram
Twist Bioscience Legal Notice Regarding Forward-Looking
Statements
This press release contains forward-looking statements. All
statements other than statements of historical facts contained
herein are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995, including, but not limited to, statements regarding the
ability of the Twist cfDNA Library Preparation Kit to maximize the
number of unique cfDNA molecules that are captured in library
preparation, push the limit of detection and detect lower frequency
variants that can be missed by other on market library preparation
solutions, address challenges associated with library preparation
from circulating cfDNA with reliable and robust performance from as
little as 1ng sample input, and detect rare allele variants.
Forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause Twist
Bioscience’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others, the
ability to achieve the expected benefits of Twist Bioscience’s
restructuring activities and reduced investments in DNA data
storage; the ability to attract new customers and retain and grow
sales from existing customers; the ability of Twist Bioscience to
achieve sufficient revenue to achieve or maintain positive cash
flow from operations or profitability in any given period; risks
and uncertainties of rapidly changing technologies and extensive
competition in synthetic biology that could make the products Twist
Bioscience is developing obsolete or non-competitive; uncertainties
of the retention of significant customers; the ability of Twist
Bioscience to successfully integrate acquired companies and to
achieve expected benefits from acquisitions; supply chain and other
disruptions; risks of third party claims alleging infringement of
patents and proprietary rights or seeking to invalidate Twist
Bioscience’s patents or proprietary rights; and the risk that Twist
Bioscience’s proprietary rights may be insufficient to protect its
technologies. For a description of the risks and uncertainties that
could cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Twist
Bioscience’s business in general, see Twist Bioscience’s risk
factors set forth in Twist Bioscience’s Quarterly Report on Form
10-Q filed with the Securities and Exchange Commission on February
2, 2024 and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and Twist Bioscience specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206958346/en/
For Investors: Angela Bitting SVP, Corporate Affairs
925-202-6211 abitting@twistbioscience.com
For Media: Amanda Houlihan Communications Manager
774-265-5334 ahoulihan@twistbioscience.com
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jun 2024 to Jul 2024
Twist Bioscience (NASDAQ:TWST)
Historical Stock Chart
From Jul 2023 to Jul 2024